G 305

Drug Profile

G 305

Alternative Names: Cancer vaccine NY-ESO-1 - Immune Design; G-305; ID-G305; IDC-G305; NY-ESO-1/GLA-SE cancer vaccine - Immune Design

Latest Information Update: 19 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immune Design
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Sarcoma

Most Recent Events

  • 10 Mar 2016 G 305 receives Orphan Drug status for Soft tissue sarcoma in European Union
  • 08 Jan 2016 G 305 receives Orphan Drug status for Soft tissue sarcoma in USA
  • 13 May 2015 Interim efficacy and adverse events data from a phase I trial in Cancer released by Immune Design
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top